Article

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder - A second multicenter, randomized, double-blind, placebo-controlled study

Bristol-Myers Squibb, Wallingford, CT 06492, USA.
Journal of Clinical Psychopharmacology (Impact Factor: 3.76). 05/2008; 28(2):156-65. DOI: 10.1097/JCP.0b013e31816774f9
Source: PubMed

ABSTRACT Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at least 1 and up to 3 historical and 1 additional prospective ADT. The study comprised a 7-28-day screening, an 8-week prospective treatment, and a 6-week randomization phase. During prospective treatment, patients experiencing a major depressive episode (17-item Hamilton Rating Scale for Depression total score >18) received single-blind adjunctive placebo plus clinicians' choice of ADT (escitalopram, fluoxetine, paroxetine controlled-release, sertraline, or venlafaxine extended-release). Subjects with inadequate response were randomized to adjunctive placebo (n = 190) or adjunctive aripiprazole (n = 191) (starting dose 5 mg/d, dose adjustments 2-20 mg/d, mean end-point dose of 11.0 mg/d). The primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale total score from end of prospective treatment phase to end of randomized treatment phase (last observation carried forward). Mean change in Montgomery-Asberg Depression Rating Scale total score was significantly greater with adjunctive aripiprazole than placebo (-8.5 vs -5.7; P = 0.001). Remission rates were significantly greater with adjunctive aripiprazole than placebo (25.4% vs 15.2%; P = 0.016) as were response rates (32.4% vs 17.4%; P < 0.001). Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4.2% vs 25.9%), headache (10.5% vs 9.0%), and fatigue (3.7% vs 10.1%). Incidence of adverse events leading to discontinuation was low (adjunctive placebo [1.1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT.

1 Follower
 · 
220 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the last decade accumulating evidence suggests that brain dopamine (DA) has a role in depression, particularly given the high comorbidity of depression with Parkinson's Disease (PD) and the antidepressant effects of the DA receptor subtype 3 (D3R) agonist pramipexole. The present study assesses the role of D3R in depression. Here we hypothesized that D3R mediates the antidepressant effects of DA. Thus, genetic deficiency of D3R in D3R knockout (D3RKO) mice would yield animals with chronic depressive symptoms. Whereas D3R deficient mice did not show significant alterations in locomotion when tested in the openfield, these animals showed anxiety-like symptoms measured as a significant increase in thigmotaxis at the openfield and a significantly lower time spent in the lit compartment at the light/dark exploration test. D3RKO animals also showed depressive-like symptoms as measured by increased immobility time in the Porsolt forced swim test and the tail suspension test, as well as anhedonia measured in the non-motor dependent sucrose test. In conclusion, D3R deficiency results in anxiety-like and depressive-like symptoms that cannot be attributed to motor dysfunction. Words: 181.
    Behavioural Brain Research 08/2014; 274. DOI:10.1016/j.bbr.2014.07.055 · 3.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIF : La dépression est une maladie fréquente, grave et invalidante pour laquelle des traitements ont montré leur efficacité. Nous avons souhaité connaître les prescriptions médicamenteuses de sortie des patients hospitalisés pour dépression unipolaire au Centre Hospitalier du Rouvray en 2012 et évaluer leur adéquation aux recommandations. Afin de mieux appréhender la concordance avec les recommandations, nous avons analysé les prescriptions d’antipsychotiques dans l’épisode dépressif majeur en 2005, époque à laquelle ces stratégies n’étaient pas recommandées. METHODE : Les prescriptions médicamenteuses et les codes diagnostics des patients hospitalisés en 2012 ont été extraits et traités informatiquement pour ne conserver que les patients hospitalisés pour dépression unipolaire avec ou sans comorbidités psychiatriques. Ils ont ensuite été analysés et fait l’objet de comparaison en fonction de la sévérité de l’accès. RESULTATS : 424 patients répondaient aux critères d’inclusion. La majorité des patients étaient hospitalisés pour dépression sévère et la moitié présentaient une comorbidité d’abus- dépendance de substance, anxieuse ou de personnalité. Quatre-vingt-six pourcent des patients prenaient un antidépresseur. Une stratégie d’augmentation était présente chez 40% des patients et de manière significativement plus fréquente chez les patients sévères (51% versus 28%). En dehors des traitements sédatifs, les traitements les plus souvent associés aux antidépresseurs étaient les antipsychotiques de seconde génération (30%) les anticonvulsivants (10%) et le lithium (7%). Les antipsychotiques de seconde génération étaient significativement plus prescrits en 2012 qu’en 2005. CONCLUSION : Le traitement de la dépression au Centre Hospitalier du Rouvray en 2012 était conforme aux recommandations.
    10/2013, Supervisor: Pr. O. GUILLIN
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This randomized, placebo-controlled study evaluated the efficacy and safety of a fixed dose (3mg/day) and flexible dose (3-15mg/day) schedule of aripiprazole as augmentation therapy in Japanese patients with inadequate response to antidepressant therapy (ADT). During an 8-week prospective treatment phase, patients experiencing a major depressive episode received clinicians' choice of ADT. Subjects with inadequate response to ADT were randomized to receive adjunctive treatment with placebo (n=195), fixed dose aripiprazole (n=197) or flexible dose aripiprazole (n=194) for 6 weeks. The primary efficacy endpoint was mean change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from the end of prospective treatment (baseline) to the end of randomized treatment. More than 90% of patients in all treatment groups completed the 6-week double-blind treatment phase. Mean MADRS total score was improved to a significantly greater extent with fixed dose aripiprazole and flexible dose aripiprazole (-10.5 and -9.6, respectively) than with placebo (-7.4). Aripiprazole was well tolerated. The incidence of akathisia observed in the flexible dose group may relate to a higher prevalence of the CYP2D6(*)10 allele in Asian populations. Six weeks of adjunctive treatment is insufficient to draw conclusions about the long-term benefits of aripiprazole. Exclusion of patients with established medical comorbidities does not reflect real-world practice. Aripiprazole augmentation at a fixed or flexible dose was superior to ADT alone and was reasonably well tolerated in Japanese patients with inadequate response to ADT. ClinicalTrials.gov identifier NCT00876343.
    Journal of Affective Disorders 08/2013; 151(3). DOI:10.1016/j.jad.2013.07.035 · 3.71 Impact Factor